Trial Profile

A Phase I/II study of NV-CoV-2

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 21 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NV CoV 2 (Primary)
Indications COVID 2019 infections; Respiratory syncytial virus infections
Focus Adverse reactions; Therapeutic Use
Sponsors NanoViricides

Most Recent Events

19 Aug 2024 According to a NanoViricides media release, the company is preparing for novel Phase II clinical trial design to evaluate the effectiveness of NV-387 against RSV, Influenza, and COVID in a single clinical trial.
30 Apr 2024 According to a NanoViricides media release, the company have begun clinical trial design for a Phase II trial to evaluate NV-387 effectiveness in RSV patients. and planning to submit a pre-IND application with the US FDA given given the extremely broad antiviral spectrum of NV-387 in order to obtain substantive input to further direct our clinical trial design efforts.
21 Nov 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com